Filing Details
Apimeds Pharmaceuticals US, Inc. (AMEX:APUS) filed a Form 8-K with the Securities and Exchange Commission on October 13, 2026, disclosing a material event.
8k filedAMEX:APUS
Apimeds Pharmaceuticals US, Inc. (APUS) Reports Material Event to SEC
Apimeds Pharmaceuticals US, Inc. (AMEX:APUS) filed a Form 8-K with the Securities and Exchange Commission on October 13, 2026, disclosing a material event.
At publication ·
What changed
Apimeds Pharmaceuticals US, Inc. (AMEX:APUS) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Apimeds Pharmaceuticals US, Inc. filed a Form 8-K on October 13, 2026, disclosing a material event to shareholders.
- The healthcare company's stock trades at $4.62 with a market capitalization of $17.1 million.
- Material events disclosed in 8-K filings include leadership changes, acquisitions, asset sales, or financial guidance modifications.
- All SEC filings for Apimeds are publicly available through the SEC's EDGAR database for investor review.
Market Context
Apimeds Pharmaceuticals US, Inc.'s stock currently trades at $4.62 with a market capitalization of $17.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Apimeds Pharmaceuticals US, Inc.'s stock.
All SEC filings for Apimeds Pharmaceuticals US, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View APUS Stock Page
Frequently Asked Questions
Where can I read APUS's SEC filings?
Browse all filings on our APUS SEC filings page.
What types of SEC filings does Apimeds Pharmaceuticals US, Inc. file?
Public companies like Apimeds Pharmaceuticals US, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.